Introgen Reports Additional Efficacy Data for Cancer Drug Advexin

Introgen Therapeutics announced that additional efficacy data Phase 3 clinical trial of Advexin in head and neck cancer patients achieved statistically significant benefits in tumor response rate, six-month survival, and overall survival.
RTTNews